A comparitive study on levels of sirt 1 and antioxidant status in type 2 diabetic and diabetic nephropathic patients - A case control study

Q3 Pharmacology, Toxicology and Pharmaceutics

Current Trends in Biotechnology and Pharmacy Pub Date : 2020-07-29 DOI:10.5530/ctbp.2020.2.18

S. Haripriya, Kedari Kedari Gsr

{"title":"A comparitive study on levels of sirt 1 and antioxidant status in type 2 diabetic and diabetic nephropathic patients - A case control study","authors":"S. Haripriya, Kedari Kedari Gsr","doi":"10.5530/ctbp.2020.2.18","DOIUrl":null,"url":null,"abstract":"A comparitive of sirt 1 and antioxidant status in type 2 diabetic and diabetic nephropathic patients Abstract Diabetic nephropathy is a leading cause of end-stage renal failure worldwide. Its morphologicc haracteristics include glomerular hypertrophy, basement membrane thickening, mesangial expansion, tubular atrophy, interstitial fibrosis and arteriolar thickening. All of these are part and parcel of micro vascular complications of diabetes. Previous study evidences indicates that oxidative stress is the common denominator link for the major pathways involved in the development and progression of diabetic microas well as macro vascular complications of diabetes. SIRT1 deacetylates target proteins using the coenzyme NAD+ and is therefore linked to cellular energy metabolism and the redox state through multiple signalling and survival pathways. SIRT1 deficiency under various stress conditions, such as metabolic or oxidative stress or hypoxia, is implicated in the pathophysiologies of agerelated diseases including diabetes, cardio vascular diseases, neurodegenerative disorders and renal diseases.","PeriodicalId":10980,"journal":{"name":"Current Trends in Biotechnology and Pharmacy","volume":"14 1","pages":"174-181"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Trends in Biotechnology and Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5530/ctbp.2020.2.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

A comparitive of sirt 1 and antioxidant status in type 2 diabetic and diabetic nephropathic patients Abstract Diabetic nephropathy is a leading cause of end-stage renal failure worldwide. Its morphologicc haracteristics include glomerular hypertrophy, basement membrane thickening, mesangial expansion, tubular atrophy, interstitial fibrosis and arteriolar thickening. All of these are part and parcel of micro vascular complications of diabetes. Previous study evidences indicates that oxidative stress is the common denominator link for the major pathways involved in the development and progression of diabetic microas well as macro vascular complications of diabetes. SIRT1 deacetylates target proteins using the coenzyme NAD+ and is therefore linked to cellular energy metabolism and the redox state through multiple signalling and survival pathways. SIRT1 deficiency under various stress conditions, such as metabolic or oxidative stress or hypoxia, is implicated in the pathophysiologies of agerelated diseases including diabetes, cardio vascular diseases, neurodegenerative disorders and renal diseases.

查看原文本刊更多论文

2型糖尿病和糖尿病肾病患者sirt1水平和抗氧化状态的比较研究——一项病例对照研究

2型糖尿病和糖尿病肾病患者sir1和抗氧化状态的比较摘要糖尿病肾病是世界范围内终末期肾功能衰竭的主要原因。其形态学特征包括肾小球肥大、基底膜增厚、系膜扩张、肾小管萎缩、间质纤维化和小动脉增厚。这些都是糖尿病微血管并发症的重要组成部分。既往研究表明，氧化应激是糖尿病微血管和大血管并发症发生发展的主要途径的共同环节。SIRT1使用辅酶NAD+使靶蛋白去乙酰化，因此通过多种信号传导和生存途径与细胞能量代谢和氧化还原状态相关。在各种应激条件下，如代谢或氧化应激或缺氧，SIRT1缺乏与衰老相关疾病的病理生理有关，包括糖尿病、心血管疾病、神经退行性疾病和肾脏疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Trends in Biotechnology and Pharmacy Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

0.70

自引率

0.00%

发文量

期刊介绍： The Association of Biotechnology and Pharmacy (ABAP) will be useful to form a forum for scientists so that they can bring together to discuss and find scientific solutions to the problems of society. The annual meetings will help the members to share their knowledge and publish their research knowledge particularly by members and fellows of the Association and special care will be taken to provide an opportunity for young scientists. Besides this the association is planned to organize symposia, seminars and workshops on current developments of Biotechnology and Pharmacy particularly on the subject of current scientific interest, and the proceedings of which will be published regularly. And in view of the vast development of science and to disseminate the problems in publication of research work, an international journal of Current Trends in Biotechnology and Pharmacy has been started by ABAP.